Human Stem Cell-Derived Cardiomyocytes in Cellular Impedance Assays: Bringing Cardiotoxicity Screening to the Front Line

Cardiovascular Toxicology

Volumn 15, Issue 2, 2015, Pages 127-139

  Peters, Matthew F ^a   Lamore, Sarah D ^a   Guo, Liang ^b   Scott, Clay W ^a   Kolaja, Kyle L ^c  

^a ASTRAZENECA   (United Kingdom)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c Cellular Dynamics International Inc   (United States)

Author keywords

Arrhythmia; Cardiomyocyte; Cardiotoxicity; Cellular impedance; Contractility; Kinase inhibitor; Stem cell

Indexed keywords

CARDIOTOXIN;

ANIMAL; CARDIOTOXICITY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HEART CONTRACTION; HEART MUSCLE CELL; HUMAN; IMPEDANCE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL;

ANIMALS; CARDIOTOXICITY; CARDIOTOXINS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTRIC IMPEDANCE; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; STEM CELLS;

EID: 84937758678     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-014-9268-9     Document Type: Article

References (52)

1. Shah, R. R. (2006). Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics,6, 889–908.
2. McGuinness, R. P., Proctor, J. M., Gallant, D. L., van Staden, C. J., Ly, J. T., Tang, F. L., et al. (2009). Enhanced selectivity screening of GPCR ligands using a label-free cell based assay technology. Combinational Chemistry and High Throughput Screening,12(8), 812–823.
3. Stevens, J. L., & Baker, T. K. (2009). The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discovery Today,3–4, 162–167.
4. Ciambrone, G. J., Liu, V. F., Lin, D. C., McGuinness, R. P., Leung, G. K., & Pitchford, S. (2004). Cellular dielectric spectroscopy: A powerful new approach to label-free cellular analysis. Journal of Biomolecular Screening,6, 467–480.
5. Giaever, I., & Keese, C. R. (1991). Micromotion of mammalian cells measured electrically. Proceedings of the National Academy of Science,17, 7896–7900.
6. Scott, C. W., & Peters, M. F. (2010). Label-free whole-cell assays: Expanding the scope of GPCR screening. Drug Discovery Today,17–18, 704–716.
7. Xi, B., Wang, T., Li, N., Ouyang, W., Zhang, W., Wu, J., et al. (2011). Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. Journal of the Association for Laboratory Automation,6, 415–421.
8. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. British Journal of Pharmacology,5, 1424–1441.
9. Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., et al. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicological Sciences,1, 281–289.
10. Parsons, J. T., Horwitz, A. R., & Schwartz, M. A. (2010). Cell adhesion: Integrating cytoskeletal dynamics and cellular tension. Nature Reviews Molecular Cell Biology,9, 633–643.
11. Layland, J., & Kentish, J. C. (1999). Positive force- and [Ca2+]i-frequency relationships in rat ventricular trabeculae at physiological frequencies. American Journal of Physiology,1(Pt 2), H9–H18.
12. Lieu, D. K., Liu, J., Siu, C. W., McNerney, G. P., Tse, H. F., Abu-Khalil, A., et al. (2009). Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells and Development,10, 1493–1500.
13. Delcarpio, J. B., Claycomb, W. C., & Moses, R. L. (1989). Ultrastructural morphometric analysis of cultured neonatal and adult rat ventricular cardiac muscle cells. American Journal of Anatomy,4, 335–345.
14. Germanguz, I., Sedan, O., Zeevi-Levin, N., Shtrichman, R., Barak, E., Ziskind, A., et al. (2011). Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. Journal of Cellular and Molecular Medicine,1, 38–51.
15. Dibb, K. M., Eisner, D. A., & Trafford, A. W. (2007). Regulation of systolic [Ca2+]i and cellular Ca2+ flux balance in rat ventricular myocytes by SR Ca2+ L-type Ca2+ current and diastolic [Ca2+]i. The Journal of Physiology,2, 579–592.
16. Korhonen, T., Hanninen, S. L., & Tavi, P. (2009). Model of excitation-contraction coupling of rat neonatal ventricular myocytes. Biophysical Journal,3, 1189–1209.
17. Peters, M. F., Scott, C. W., Ochalski, R., & Dragan, Y. P. (2012). Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications. Assay and Drug Development Technologies,6, 525–532.
18. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., & Kroemer, G. (2011). Cell death assays for drug discovery. Nature Reviews Drug Discovery,3, 221–237.
19. Lamore, S. D., Kamendi, H. W., Scott, C. W., Dragan, Y. P., & Peters, M. F. (2013). Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicological Sciences,2, 402–413.
20. Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y. W., Funes, C., et al. (2013). Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. Journal of Biomolecular Screening,1, 39–53.
21. Schiller, L. R., & Johnson, D. A. (2008). Balancing drug risk and benefit: Toward refining the process of FDA decisions affecting patient care. American Journal of Gastroenterology,4, 815–819.
22. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research,1, 32–45.
23. Lu, H. R., Vlaminckx, E., Hermans, A. N., Rohrbacher, J., Van Ammel, K., Towart, R., et al. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. British Journal of Pharmacology,7, 1427–1438.
24. Guo, L., Coyle, L., Abrams, R. M., Kemper, R., Chiao, E. T., & Kolaja, K. L. (2013). Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological Sciences,2, 581–594.
25. Gintant, G. (2011). An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacology & Therapeutics,2, 109–119.
26. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., & Stockbridge, N. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium. American Heart Journal,3, 292–300.
27. Jonsson, M. K., Wang, Q. D., & Becker, B. (2011). Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay and Drug Development Technologies,6, 589–599.
28. Nguemo, F., Saric, T., Pfannkuche, K., Watzele, M., Reppel, M., & Hescheler, J. (2012). In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cellular Physiology and Biochemistry,5–6, 819–832.
29. Chi, K. R. (2013). Regulatory watch: Speedy validation sought for new cardiotoxicity testing strategy. Nature Reviews Drug Discovery,9, 655.
30. Mellor, H. R., Bell, A. R., Valentin, J. P., & Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicological Sciences,1, 14–32.
31. Harmer, A. R., Abi-Gerges, N., Morton, M. J., Pullen, G. F., Valentin, J. P., & Pollard, C. E. (2012). Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicology and Applied Pharmacology,2, 162–172.
32. Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nature Reviews Drug Discovery,2, 111–126.
33. Doherty, K. R., Wappel, R. L., Talbert, D. R., Trusk, P. B., Moran, D. M., Kramer, J. W., et al. (2013). Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicology and Applied Pharmacology,1, 245–255.
34. Cohen, J. D., Babiarz, J. E., Abrams, R. M., Guo, L., Kameoka, S., Chiao, E., et al. (2011). Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicology and Applied Pharmacology,1, 74–83.
35. Lim, J., Taoka, B. M., Lee, S., Northrup, A., Altman, M., Sloman, D., et al. (2011). Pyrazolo[1,5-A]pyrimidines as MARK inhibitors. World Patent WO 2011/087999 A1, 21 July 2011.
36. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology,11, 1039–1045.
37. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., et al. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology,11, 1046–1051.
38. Carlson, C., Koonce, C., Aoyama, N., Einhorn, S., Fiene, S., Thompson, A., et al. (2013). Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. Journal of Biomolecular Screening,10, 1203–1211.
39. Satoh, H., Delbridge, L. M., Blatter, L. A., & Bers, D. M. (1996). Surface:volume relationship in cardiac myocytes studied with confocal microscopy and membrane capacitance measurements: Species-dependence and developmental effects. Biophysical Journal,3, 1494–1504.
40. Feinberg, A. W., Alford, P. W., Jin, H., Ripplinger, C. M., Werdich, A. A., Sheehy, S. P., et al. (2012). Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials,23, 5732–5741.
41. Blazeski, A., Zhu, R., Hunter, D. W., Weinberg, S. H., Zambidis, E. T., & Tung, L. (2012). Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Progress in Biophysics and Molecular Biology,2–3, 166–177.
42. Uppal H. (2013). Harnessing stem cells for predictive toxicology: Meeting the challenges of drug discovery today. http://webinar.sciencemag.org/webinar/archive/harnessing-stem-cells-predictive-toxicology#speaker-bio-467. Accessed July 17, 2013.
43. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? British Journal of Pharmacology,4, 675–693.
44. Liang, P., Lan, F., Lee, A. S., Gong, T., Sanchez-Freire, V., Wang, Y., et al. (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation,16, 1677–1691.
45. Harris, K., Aylott, M., Cui, Y., Louttit, J. B., McMahon, N. C., & Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicological Sciences,2, 412–426.
46. Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., et al. (2013). Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation,11(Suppl 1), S3–S13.
47. Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., & Rusyn, I. (2013). Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicology and Applied Pharmacology,3, 500–507.
48. Cerignoli, F., Charlot, D., Whittaker, R., Ingermanson, R., Gehalot, P., Savchenko, A., et al. (2012). High throughput measurement of Ca(2)(+) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. Journal of Pharmacological and Toxicological Methods,3, 246–256.
49. Alford, P. W., Feinberg, A. W., Sheehy, S. P., & Parker, K. K. (2010). Biohybrid thin films for measuring contractility in engineered cardiovascular muscle. Biomaterials,13, 3613–3621.
50. Pointon, A., Abi-Gerges, N., Cross, M. J., & Sidaway, J. E. (2013). Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicological Sciences,2, 317–326.
51. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature,6868, 198–205.
52. Scott, C. W., Peters, M. F., & Dragan, Y. P. (2013). Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicology Letters,1, 49–58.